Lineage Cell Therapeutics, Inc.
LCTX
$0.485
-$0.015-3.00%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 6.19% | -0.60% | -41.22% | -32.48% | -39.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.19% | -0.60% | -41.22% | -32.48% | -39.16% |
| Cost of Revenue | -21.80% | 8.73% | 63.08% | 212.60% | 2,149.45% |
| Gross Profit | 55.50% | -31.83% | -519.86% | -202.59% | -153.17% |
| SG&A Expenses | 31.94% | -16.32% | -20.20% | -25.15% | -38.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.75% | -17.36% | -17.10% | -15.58% | -19.01% |
| Operating Income | -1.30% | 23.23% | 6.33% | 6.78% | 5.85% |
| Income Before Tax | 20.19% | 19.59% | -3.67% | 5.19% | 9.80% |
| Income Tax Expenses | -- | 100.00% | 100.00% | 100.00% | -433.27% |
| Earnings from Continuing Operations | 13.49% | 13.32% | -9.59% | 0.13% | 18.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -285.71% | -204.84% | -73.77% | -121.70% | -108.75% |
| Net Income | 13.39% | 12.81% | -9.82% | -0.42% | 18.22% |
| EBIT | -1.30% | 23.23% | 6.33% | 6.78% | 5.85% |
| EBITDA | -1.75% | 23.66% | 6.35% | 6.89% | 5.88% |
| EPS Basic | 22.83% | 18.44% | -3.71% | 2.96% | 19.59% |
| Normalized Basic EPS | 17.58% | 37.50% | 15.38% | 19.20% | 15.84% |
| EPS Diluted | 22.83% | 18.44% | -3.71% | 3.10% | 19.69% |
| Normalized Diluted EPS | 17.58% | 37.50% | 15.38% | 19.20% | 15.84% |
| Average Basic Shares Outstanding | 15.95% | 7.29% | 6.04% | 3.49% | 1.68% |
| Average Diluted Shares Outstanding | 15.95% | 7.29% | 6.04% | 3.49% | 1.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
